The efficiency of five different cryopreservation protocols (our original controlled-rate and noncontrolled-rate protocols) was evaluated on the basis of the recovery after thawing of very primitive pluripotent hemopoietic stem cells (MRA CFU-GM ), pluripotent progenitors (CFUSd12) and committed granulocyte-monocyte progenitors (CFU-GM) in mouse bone marrow. Although the nucleated cell recovery and viability determined immediately after the thawing and washing of the cells were found to be similar, whether controlled-rate or noncontrolled-rate cryopreservation protocols were used, the recovery of MRA CFU-GM , CFU-Sd12 and CFU-GM varied depending on the type of protocol and the cryoprotector (DMSO) concentrations used. It was shown that the controlled-rate protocol was more efficient, enabling better MRA CFU-GM , CFU-Sd12 and CFU-GM recovery from frozen samples. The most efficient was the controlled-rate protocol of cryopreservation designed to compensate for the release of fusion heat, which enabled a better survival of CFU-Sd12 and CFU-GM when combined with a lower (5%) DMSO concentration. On the contrary, a satisfactory survival rate of very primitive stem cells (MRA CFU-GM ) was achieved only when 10% DMSO was included with a fivestep protocol of cryopreservation. These results point to adequately used controlled-rate freezing as essential for a highly efficient cryopreservation of some of the categories of hematopoietic stem and progenitor cells. At the same time, it was obvious that a higher DMSO concentration was necessary for the cryopreservation of very primitive stem cells, but not, however, for more mature progenitor cells (CFU-S, CFU-GM). These results imply the existence of a mechanism that decreases the intracellular concentration of DMSO in primitive MRA cells, which is not the case for less primitive progenitors.
acceptable cell yield and recovery. The application of cryobiology in cellular preservation started in 1949 with the freezing of fowl sperm, using glycerol as a cryoprotectant. 10 Subsequently, this procedure was applied to the cryopreservation of blood cells 11 and of HSPCs, collected from bone marrow or peripheral blood, [12] [13] [14] [15] which have led to their successful clinical application in transplantation, as well as in establishing practical and effective gene therapy protocols. 16 The aim of various cryopreservation procedures is to minimize cell injury during the freeze-thaw process (cryoinjuries). The cell injury may be the result of: (1) extensive cellular dehydration ('solution effect') and/or (2) intracellular ice crystallization ('mechanical cell damage'). [6] [7] [8] For successful HSPC cryopreservation, a cryoprotective agent which decreases the osmotic gradient and the vapor pressure difference between the intra-and extracellular compartments is needed. Dimethyl sulfoxide (DMSO) has been commonly used as a cryoprotectant in different (2.2-10%) concentrations. 9, [17] [18] [19] [20] Finally, a higher degree of cell destruction has been observed when the transition period from liquid to solid phase (release of the fusion heat) was prolonged. 9, 21 Although HSPC cryopreservation procedures are already in routine use, some problems related to the optimal cooling velocity during controlled-rate freezing and the choice of the cryoprotective agent at the appropriate concentration are still unresolved.
The purpose of this study was to compare the efficacy of different cryopreservation protocols on the basis of the recovery of very primitive pluripotent stem cells determined by marrow repopulating ability assay (MRA), pluripotent progenitors (CFU-Sd12 = colony-forming unit spleen day 12) and committed granulocyte-monocyte progenitors (CFU-GM) from cryopreserved murine bone marrow samples. The cryopreservation was achieved using two of our original controlled-rate and one noncontrolled-rate freezing procedures, where different concentrations of DMSO were applied.
Materials and methods

Experimental animals
Three separate experiments were carried out on CBA/Hmice of both sexes, weighing 20-22 g when 12-15 weeks old (Military Medical Academy, Belgrade, Yugoslavia). The mice (six to seven animals in each experiment) were used to obtain bone marrow cells for both the in vitro (CFU-GM) and the in vivo (CFU-Sd12 and MRA) experiments. The mice were sacrificed by cervical dislocation. Cells from both femurs were flushed out with Dulbecco's modification of Eagle's medium (DMEM) and subsequently pooled, washed and resuspended in DMEM, as described previously. 22 Lethally irradiated mice of the same strain and age were used as recipients of bone marrow cells in the CFU-S assay.
Cryopreservation protocols
For the freezing of murine bone marrow cells, DMSO (Serva Feinbiochemica, New York, NY, USA) at a final concentration of 5 or 10% in DMEM with 10% fetal calf serum (FCS, Flow Laboratories, Irvine, UK) was used as a cryoprotective agent. 23, 24 Equilibration was performed at 0°C for 5 min. During cryopreservation, cell suspension samples (2 ml) were stored in sterile, thermo-stable, plastic tubes.
The noncontrolled-rate freezing procedure (cryopreservation protocol 3) was performed after cell equilibration with 10% DMSO. Following equilibration the cells were immediately placed into a freezer at −90 ± 5°C (Eurospital SPA, 3253; Congelatore, Trieste, Italy) where they remained until thawing. Controlled-rate freezing procedures (protocols 1, 2, 4 and 5) were accomplished by Planer R203/200R (Planer Products, Sunbury-on-Thames, UK). Our original procedures for controlled-rate freezing consisted of a five-step -procedure 1 (Figure 1 ) or a fourstep -procedure 2 ( Figure 2 ).
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Table 1
Cryopreservation protocols for HSPCs of CBA-mice The cryopreservation protocols used are presented in Table 1 .
Protocols
Controlled-rate freezing procedures were performed at a temperature of −70°C for 54 min (procedure 1) or for 59 min (procedure 2).
After completion of freezing by all protocols employed, the cell suspensions were placed into a mechanical freezer at a temperature of −90 ± 5°C for 1-6 months, ie to the moment of thawing and the investigations that followed. The cell samples were thawed in a water bath at 37 ± 3°C. The cryoprotective agent present in thawed cell samples was removed by a washing procedure with DMEM, centrifugation for 15 min at 600 g, which was followed by cell resuspension in DMEM. 23 
Cell quantification methods
The nucleated cell (NC) number in the bone marrow cell suspensions was quantified in a Spencer's hemocytometer chamber after dilution with Türck's solution. 21 The viability of the cells was evaluated using the trypan blue exclusion test. [21] [22] [23] [24] For the CFU-GM assay a culture mixture with 5 × 10 4 cells/ml was prepared. 22, 23 The culture mixture consisted of 20% FCS, 10 −4 m alpha-thioglycerol, and 0.8% methylcellulose in DMEM. As a source of colony-stimulating activity (CSA), lung-conditioned medium (LCM) at 5, 15 or 20% concentrations was used. 22 The triplicate cultures in the CFU-GM assay were incubated for 7 days at 37°C, in an atmosphere of 5% CO 2 and 100% humidity. Colonies (more than 50 cells) were counted using an inverted microscope. [22] [23] [24] The number of CFU-GM obtained was normalized to the total number of cells in the particular sample before and after cryopreservation, and on the basis of this calculation CFU-GM recovery was expressed as the percentage of CFU-GM recovered after cryopreservation in comparison to the value before cryopreservation.
The CFU-S determination was performed according to the procedure described by Till and McCulloch. 25 The recipient mice were irradiated with 9 Gy X-irradiation at the dose rate 0.959 Gy/min (RT 305; Philips, Amsterdam, The Netherlands), as described previously. 26, 27 The irradiation resulted in complete depletion of CFU-S in the recipient mice; ie endogenous colonies were not detected. Groups of eight to 10 recipient mice were injected with previously cryopreserved (five different protocols) or unfrozen cells (control group), 4-6 × 10 4 bone marrow cells which were resuspended in a volume of 0.2 ml DMEM, to obtain a countable number of colonies. 26, 27 The spleens of these recipients were removed 12 days later (CFU-Sd12 assay) and fixed in Telleyesniczky's fluid (consisting of 87% of 70% ethanol, 4.3% of glacial acetic acid, and 8.7% of formaldehyde) for the counting of spleen colonies. The number of CFU-Sd12, which is considered to be a more primitive population of pluripotent progenitors than CFUSd8 or CFU-Sd9, 28 was calculated per 10 5 cells injected, as described previously, 26, 27 and multiplied by the number of cells present in the corresponding sample before and after cryopreservation. The CFU-Sd12 recovery was presented as the percentage of the number of CFU-Sd12 in the tested sample after cryopreservation in comparison to the value obtained before cryopreservation.
MRA was estimated on the basis of the number of the newly generated CFU-GM in the bone marrow of irradiated mice 14 days after inoculation of the test bone marrow cell suspension. 29, 30 The mice were irradiated as described above for CFU-S assay, and injected with 1.5-5 × 10 5 fresh or previously frozen and thawed cells. Fourteen days after the injection, mice (five to seven in each group) were sacrificed, the femurs were flushed with DMEM, and an appropriate number of cells (5-10 × 10 4 ) was plated in methylcellulose culture mixture. The CFU-GM number was determined as described above and calculated per one femur of the recipient mice. This number represents the MRA of the test sample inoculated in one mouse. The results were then normalized to 1 × 10 6 theoretically injected cells, and these values represented the standard MRA value per 1 × 10 6 cells in the particular sample tested. To derive the total MRA of the particular sample, the above value was multiplied by the actual number of cells present (expressed in millions) both before and after cryopreservation at the moment of MRA determination (injection of mice).
The MRA recovery after cryopreservation was calculated as the ratio (percentage) of the total MRA values of the particular sample before and after cryopreservation. On the other hand, a ratio between the MRA value/10 6 theoretically injected cells before and after cryopreservation indirectly represented the change in concentration (incidence) of MRA cells in the estimated sample, which is named 'concentration/dilution factor'.
Statistical analysis
The results were expressed as a mean value ± standard deviation (s.d.). Statistical analysis was performed by the ANOVA-test (Statgraf 4.0) using a personal computer. Differences were considered significant if P Ͻ 0.05. Statistical analysis of the changes in the number of CFU-GM in the samples tested before and after cryopreservation was performed using a paired test (Wilcoxon signed rank).
Results
The mean values obtained in three experiments for NC count and viability, CFU-GM and CFU-Sd12 numbers for unfrozen control murine bone marrow cells were: N NC = 3.9 ± 0.56 × 10 The NC recovery and viability were determined subsequently after thawing and washing procedures. These results are presented in Table 2 .
NC recovery was similar for controlled-rate and noncontrolled-rate cryopreservation protocols, being 87.9 ± 6.6% (protocol 4) and 70.3 ± 17.1% (protocol 3). The statistical differences in the NC recovery (cryopreserved vs control group NCs and intergroup variations between cells frozen by different protocols) were insignificant. Using either controlled-rate (protocols 1, 2, 4 and 5) or noncontrolled-rate (protocol 3) cryopreservation, NC viability was found to be high (from 87.6 ± 10.8% to 96.5 ± 7.7%).
Table 2
The recovery and viability of NCs after cryopreservation The results are mean ± s.d. The data are pooled from three experiments. NC recovery = cryopreserved/unfrozen (control group) nucleated cell count; NC VB = nucleated cell viability (determined immediately after thawing and washing of the cells). Data on CFU-GM quantification and recovery are given in Table 3. CFU-GM recovery, as well as their number, in the samples tested was the highest (73.0 ± 8.8%) when a fivestep controlled-rate freezing procedure and 5% DMSO were used. In the CFU-GM assays, the applied LCM concentrations were different, but in separate experiments for all groups of cells (unfrozen and cryopreserved by protocols 1, 2, 3, 4 or 5) the LCM concentration was the same.
Recovery of cryopreserved murine hematopoietic progenitor cells
The results of CFU-Sd12 quantification and recovery are presented in Table 4 .
The best CFU-Sd12 recovery (90.0 ± 15.9%) and the highest concentration of these cells after cryopreservation were achieved when protocol 4, the controlled-rate cryopreservation, was used.
Unlike the NC recovery and viability (Table 2) , high variations in CFU-GM and CFU-Sd12 recovery were evident after cryopreservation by different protocols in the range of 27.5 ± 3.6% to 73.0 ± 8.8% (for CFU-GM) and 37.8 ± 23.0% to 90.0 ± 15.9% (for CFU-Sd12), respectively.
Statistical analysis related to CFU-GM and CFU-Sd12 recovery has confirmed that the use of controlled-rate freezing procedure (protocol 4) causes an insignificant reduction in the number of the CFU-Sd12 in the thawed bone marrow cells vs the control group. Contrary to that, the application Table 4 The recovery of CFU-Sd12 in mice bone marrow cell suspension after cryopreservation of noncontrolled-rate freezing procedure (protocol 3) resulted in a significant (P Ͻ 0.001) reduction of the CFUSd12 number vs control group. In accordance with that finding, a significant difference in the efficiency of the two above protocols that has been found (Tables 3 and 4 ) is in favor of the controlled-rate freezing (P Ͻ 0.001). The difference between protocols 1 and 4 in respect to the CFU-GM and CFU-Sd12 recovery was significant also: P Ͻ 0.001 for CFU-GM and P Ͻ 0.05 for CFU-Sd12. Finally, the differences between protocol 2 and protocol 4 were also highly significant (in favor of protocol 4): P Ͻ 0.001 for CFU-GM and P Ͻ 0.01 for CFU-Sd12.
As regards the MRA cell recovery, it was obvious that a satisfactory cryopreservation of these cells could only be achieved with the combination of sufficient DMSO concentration and controlled-rate freezing, taking into consideration the release of the fusion heat (protocol 1) ( Table 5) .
Unlike the less primitive progenitors (Table 3 and 4), MRA cells were better preserved with 10% DMSO. When the DMSO concentration was lower, MRA recovery was approximately 1/3 regardless of the freezing protocols, thus demonstrating the importance of DMSO concentration. However, when 10% DMSO was not combined with the five-step freezing procedure, it was inefficient for the cryopreservation of MRA cells. Statistical analysis related to MRA recovery confirmed that the use of a five-step con-617 Table 5 The recovery of MRA in mice bone marrow cell suspension after cryopreservation Results are mean ± s.d. The data are pooled from three experiments. a 'Dilution factor' represents decrease in MRA concentration in the sample during certain freezing/thawing procedure. For protocol 1 this value is Ͼ1 indicating a higher concentration of MRA cells in the sample after freezing/thawing procedure than initially. b Significant difference cryopreserved cells vs control (P Ͻ 0.001).
trolled-rate freezing procedure with 10% DMSO (protocol 1) resulted in an insignificant reduction in the number of the MRA in the thawed bone marrow cells vs the control group. Only this protocol enabled an increase in MRA concentration after the freezing/thawing procedure. In contrast, the application of the cryopreservation protocols 2, 3, 4 and 5, resulted in a highly significant (P Ͻ 0.001) reduction of the MRA recovery in the thawed bone marrow cell suspension vs control group, as well as in a decrease in the number of these cells in the same samples.
Discussion
It was found in the experiments presented here that there was a significantly better recovery of bone marrow CFU-GM and CFU-Sd12 after the application of the controlledrate cryopreservation procedure in comparison to the noncontrolled-rate. This is in agreement with the results presented for bone marrow and peripheral blood hematopoietic stem or progenitor cells in human studies. 15, 20, 21, [31] [32] [33] [34] The difference in recovery of CFU-GM and CFU-Sd12 as observed here was not related to the change in the number or viability of cells after the use of controlled-rate vs noncontrolled-rate cryopreservation procedures. The recovery of CFU-GM and CFU-Sd12 was evidently better when the controlled-rate protocol 4 was used. The difference between protocol 4 in comparison to the other controlled-rate protocols (1, 2 and 5) was that in protocol 4 the lowest concentration (5%) of DMSO was combined with a five-step freezing procedure. However, when a five-step freezing procedure was performed in the presence of 10% DMSO (protocol 1) an obviously inferior recovery of both CFU-GM and CFU-Sd12 was obtained after thawing the bone marrow cells. On the contrary, 5% DMSO had no protective effect on pre-CFU-S (MRA), even if it was used in combination with a five-step freezing procedure, but a five-step protocol enabled a very good survival of pre-CFU-S in combination with 10% DMSO concentration, resulting in an increased concentration of these cells in thawed samples. The reason for the decrease in MRA using the protocols with lower DMSO concentration may be related to the loss of MRAfacilitating cells or modification of their functional capability. The results obtained imply different biological properties of very primitive stem cells in comparison to pluripotent and committed 'clonogenic' progenitors with respect to DMSO retention. It is possible that a higher extracellular DMSO concentration is required to achieve and maintain a sufficient intracellular concentration of DMSO, necessary for the cryopreservation of pre-CFU-S. Probably DMSO, like some cytostatics or rhodamin, 35 could be eliminated from very primitive stem cells by a membrane mechanism known as the P-glycoprotein transport system. This mechanism is present (with a very high frequency) 36 in leukemic stem and progenitor cells, and, if it could influence intracellular concentration of DMSO (decreased DMSO concentration below the threshold of cryoprotection), it might account for a greater sensitivity of CML stem cells (LTC-IC of CML) to cryopreservation, as noted recently by Petzer et al. 37, 38 A similar phenomenon has also been demonstrated for acute myeloid leukemia progenitors, of both human (AML) 39 and rat (BNML) 40 origin. This issue requires further investigations, extended to human stem and progenitor cells, which could potentially play an important role in the discovery of new modalities for the elimination of leukemic cells from autografts. 39 The choice of the cryoprotective agent and its optimal concentration is important for the required cell recovery after thawing. [17] [18] [19] There are several HSPC cryopreservation protocols. However, only two cryoprotective agents are in current clinical use -DMSO 13, 18, 20 and/or hydroxyethyl starch (HES), 31 but in various concentrations. Lakota and Fuchsberger 20 reported acceptable cell recovery using low DMSO concentrations (2.2 and 4.5% DMSO with 6% HES). Our results confirm an unfavorable effect of higher DMSO concentrations on the cryopreservation of 'clonogenic' progenitors, but the more primitive stem cells (pre-CFU-S) could only be well cryopreserved with a higher (10%) concentration of DMSO. This seems to be in accordance with the apparent clonogenic (CFU-GM, BFU-E) cell loss during the controlled-rate procedure of cryopreservation of human cord blood cells with 10% DMSO, which was associated with the sparing of more primitive LTC-IC (long-term culture-initiating cells). 41 However, the decrease in the number of clonogenic progenitors cryopreserved with a higher (10%) DMSO concentration as evident in our work, may not necessarily be the result of their loss. Therefore, our result can be supported by recent findings that DMSO is not toxic to human progenitors at 10% concentration, 42 but it influences the surface antigen expression 43 which could affect the homing of CFU-S in the spleen, if an analogous phenomenon exists in mouse bone marrow. According to better recovery of total viable cells (determined immediately after thawing and washing of the cells) than CFU-GM and CFU-Sd 12, it might be concluded that these progenitors are more sensitive to cryopreservation than mature (predominant) bone marrow cells, implying a different optimal cooling rate for each maturation stage. This is, however, an artifact, since the number of viable cells declined during the first 12 h after thawing, but the number of progenitors remained constant (not shown). The real recovery of the viable cells could be estimated several hours after thawing, when the delayed effects of the vital damage are completely expressed. This problem, however, does not exist for the estimation of clonogenic progenitor cell number, since the colonies can only be derived from the intact progenitors while the progenitors which are dead immediately after thawing as well as progenitors which are damaged and are going to die several hours after thawing will not produce colonies. In addition, it has been suggested 44 that a sublethal injury to CFU-GM during the cryopreservation causes hyporesponsiveness to growth factors, leading to their underestimation, rather then overestimation.
In conclusion, although there exist contradictory views about the obligatory need to compensate for heat of fusion, the results presented here point undoubtedly to the procedure with compensation of the released heat of fusion (protocols 1 and 4), being the most effective procedure for cryopreservation of bone marrow progenitor cells. However, this procedure should be combined with an adequate DMSO concentration in respect of the target cell population, where there is a need on certain occasions for such a population to be preserved.
